Zacks Investment Research upgraded shares of GenVec Inc (NASDAQ:GNVC) from a hold rating to a buy rating in a report released on Wednesday morning, Analyst Ratings.Net reports. They currently have $0.50 target price on the biopharmaceutical company’s stock.

According to Zacks, “GenVec, Inc. is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of the Company’s product candidates uses patent-protected technology to deliver genes that produce beneficial proteins. GenVec’s lead product, TNFerade is currently in a pivotal Phase II/III study in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and metastatic melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, seasonal and pandemic flu, and foot-and-mouth disease. “

GenVec (NASDAQ:GNVC) traded up 3.883% on Wednesday, hitting $0.519. 72,190 shares of the stock traded hands. The stock has a 50-day moving average price of $1.38 and a 200 day moving average price of $2.00. GenVec has a 1-year low of $0.46 and a 1-year high of $4.67. The company’s market cap is $8.96 million.

Separately, HC Wainwright reissued a buy rating on shares of GenVec in a report on Thursday, November 5th.

GenVec, Inc. (NASDAQ:GNVC) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. The Company develops and commercializes its product candidates through collaborations. In collaboration with Novartis, the Company’s hearing and balance disorders program is involved in the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. In the area of animal health, the Company, with its collaborators, is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

12 Month Chart for NASDAQ:GNVC

Get a free copy of the Zacks research report on GenVec (GNVC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GenVec Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc and related companies with MarketBeat.com's FREE daily email newsletter.